RPG Life Sciences to present at RPG Annual Investor Conference 2026 on May 26
RPG Life Sciences will present at the RPG Annual Investor Conference 2026 on May 26, 2026. The company reported FY26 revenue of ₹707.5 crore, EBITDA of ₹172.7 crore, and EPS of ₹69.6. Its Domestic Formulations business outperformed the market, growing 1.6x faster than IPM. Investments of over ₹185 crore in capex were made over five years.
This is an announcement about an upcoming investor presentation and conference. While it provides historical financial data, it does not contain new material information that would significantly impact the company's stock price or operations in the short term.
The announcement is a routine intimation about an upcoming investor presentation and conference. While it provides a summary of past performance (FY26 results), the core of the announcement is about a future event, making the sentiment neutral.
RPG Life Sciences Limited has announced its participation in the RPG Annual Investor Conference 2026. The company will be presenting an investor presentation during the conference, which is scheduled to be held on May 26, 2026.
This investor presentation is expected to cover various aspects of the company's business, including its financial performance, strategic initiatives, and future outlook. The presentation will also include forward-looking statements regarding growth strategies, business development, market position, expenditures, and financial results. RPG Life Sciences operates in the Pharmaceutical segment, with its business divided into Domestic Formulations (DF), International Formulations (IF), and Active Pharmaceutical Ingredients (APIs).
For the fiscal year 2026 (FY26), the company reported robust financial metrics, including revenue of ₹707.5 crore, an EBITDA margin of 24.4%, a Return on Capital Employed (ROCE) of 28.5%, and a Return on Equity (ROE) of 21.1%. Earnings Per Share (EPS) stood at ₹69.6. The company also highlighted its consistent outperformance in the Domestic Formulations business, which contributed 69% of sales, growing 1.6 times faster than the Indian Pharma Market (IPM) in FY26. Key strategies for this growth include focusing on high-growth therapy areas, strengthening key brands, successful new product launches, and improved field execution. The company has also invested over ₹185 crore in capital expenditure over the last five years to enhance manufacturing capabilities. Financials show a 5-year CAGR revenue growth of 12.7% and an improvement in Profit Before Tax (PBT) from 13.8% in FY21 to 21.2% in FY26. The company also reported significant improvements in environmental metrics, including a 48.5% reduction in carbon emissions and a 48% improvement in energy efficiency in FY26. The company's long-term and short-term credit ratings have been reaffirmed at A+ and A1, respectively.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.